Clare Arnott's Publications

About Clare Arnott's Publications

Global Director, Cardiovascular Program
  • Co-Director, Global Chronic & Complex Diseases
  • BMed Sci,
  • MBBS (Hons),
  • PhD,
  • FRACP,
  • FESC,
  • CF

  • Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial

    Clinical Journal of the American Society of Nephrology Date published:

  • Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease

    Clinical Journal of the American Society of Nephrology Date published:

  • Colchicine in Cardiovascular Disease: In-Depth Review.

    Circulation Date published:

  • Sex disaggregated analysis of risk factors for adverse outcomes in hypertrophic cardiomyopathy

    Date published:

  • Sex Disaggregated Analysis of Risk Factors for Adverse Outcomes in Hypertrophic Cardiomyopathy

    Heart, Lung and Circulation Date published:

  • Protocol for the Metformin Aneurysm Trial (MAT): a placebo-controlled randomised trial testing whether metformin reduces the risk of serious complications of abdominal aortic aneurysm

    Trials Date published:

  • Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial

    Journal of the American Heart Association Date published:

  • Heart Failure with Reduced Ejection Fraction-Does Sex Matter?

    Current Heart Failure Reports Date published:

  • Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials

    Cancers Date published:

  • The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms

    Cells Date published:

  • Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

    Date published:

  • Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

    European Heart Journal Date published:

  • Procedural Volumes in the Era of COVID: The Risk Versus Benefit Trade-Off

    Heart, Lung and Circulation Date published:

  • Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program

    Diabetologia Date published:

  • Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial

    European Heart Journal Date published: